Back to Results

A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children (ICON3)

Primary Objective

To determine if the proportion of patients with a platelet response is significantly greater in patients with newly diagnosed ITP treated with eltrombopag than those treated with standard first-line treatments

Study

Is this Study for You?

Let's Get Started!

Details
Age

Child

Type of Study

Treatment

Scope

National

Location

Childrens Hospital Colorado

Principal Investigator
Taizo Nakano,  MD

Taizo Nakano, MD

Study ID

Protocol Number: 18-1963

More information available at ClinicalTrials.gov: NCT03939637

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers